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A bs tr ac t
Background
The clinically appropriate range for oxygen saturation in preterm infants is unknown. 
Previous studies have shown that infants had reduced rates of retinopathy of pre-
maturity when lower targets of oxygen saturation were used.
Methods
In three international randomized, controlled trials, we evaluated the effects of 
targeting an oxygen saturation of 85 to 89%, as compared with a range of 91 to 
95%, on disability-free survival at 2 years in infants born before 28 weeks’ gestation. 
Halfway through the trials, the oximeter-calibration algorithm was revised. Re-
cruitment was stopped early when an interim analysis showed an increased rate of 
death at 36 weeks in the group with a lower oxygen saturation. We analyzed pooled 
data from patients and now report hospital-discharge outcomes.
Results
A total of 2448 infants were recruited. Among the 1187 infants whose treatment 
used the revised oximeter-calibration algorithm, the rate of death was significantly 
higher in the lower-target group than in the higher-target group (23.1% vs. 15.9%; 
relative risk in the lower-target group, 1.45; 95% confidence interval [CI], 1.15 to 
1.84; P = 0.002). There was heterogeneity for mortality between the original algo-
rithm and the revised algorithm (P = 0.006) but not for other outcomes. In all 2448 
infants, those in the lower-target group for oxygen saturation had a reduced rate of 
retinopathy of prematurity (10.6% vs. 13.5%; relative risk, 0.79; 95% CI, 0.63 to 
1.00; P = 0.045) and an increased rate of necrotizing enterocolitis (10.4% vs. 8.0%; 
relative risk, 1.31; 95% CI, 1.02 to 1.68; P = 0.04). There were no significant between-
group differences in rates of other outcomes or adverse events.
Conclusions
Targeting an oxygen saturation below 90% with the use of current oximeters in 
extremely preterm infants was associated with an increased risk of death. (Fund-
ed by the Australian National Health and Medical Research Council and others; 
BOOST II Current Controlled Trials number, ISRCTN00842661, and Australian 
New Zealand Clinical Trials Registry numbers, ACTRN12605000055606 and 
 ACTRN12605000253606.)
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The clinically appropriate range for oxygen saturation in preterm infants is un-known. Trials in the 1950s showed that 
unrestricted oxygen increased the rate of severe 
retinopathy of prematurity. However, when oxy-
gen was subsequently restricted, increased mor-
tality was observed.1 The first Benefits of Oxygen 
Saturation Targeting (BOOST) trial showed that 
in preterm infants who were still receiving oxy-
gen at 32 weeks’ gestation, targeting a higher 
oxygen-saturation range prolonged oxygen de-
pendence.2 Observational studies suggested that 
higher oxygen-saturation levels may increase rates 
of retinopathy of prematurity.3-5
In five randomized, masked trials with simi-
lar protocols conducted in the United States,6 
Australia, New Zealand, Canada, and the United 
Kingdom7 involving infants born before 28 weeks’ 
gestation, investigators are evaluating the effects 
of targeting a range of oxygen saturation of 85 
to 89%, as compared with a range of 91 to 95%, 
on survival and neurodevelopmental outcomes at 
18 months to 2 years after the expected delivery 
date. In all five trials, Masimo Radical pulse ox-
imeters were used to measure oxygen saturation.
During the trials, investigators in the United 
Kingdom found that standard Masimo Radical 
oximeters returned fewer oxygen-saturation values 
in the range of 87 to 90% than expected.8 We 
investigated this oximeter finding, because such 
a discrepancy might affect the study groups dif-
ferently, and we found that there was a shift up 
in the oximeter-calibration curve between 87% 
and 90%. This reduced the frequency of dis-
played oxygen-saturation values ranging from 
87 to 90% and caused values ranging from 87 to 
96% to read 1 to 2% higher. Masimo supplied 
software with a revised calibration algorithm 
that eliminated the problem and was similar to 
the calibration of other oximeters.8
Approximately halfway through the trials, be-
tween December 2008 and May 2009, oximeters 
in the United Kingdom and Australian trials 
were changed to the new calibration algorithm, 
and the new algorithm was used for all infants 
who were subsequently enrolled. The New Zealand 
trial oximeters were not changed because recruit-
ment had nearly finished. Analysis of oxygen-
saturation distributions showed that the revised 
calibration algorithm improved oxygen-satura-
tion targeting, with clearer separation in oxygen-
saturation patterns between the two study groups 
and more time in the intended oxygen-satura-
tion range (Fig. 1, and Tables S1.1 through S1.4 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org).
In 2010, in the Surfactant, Positive Pres-
sure, and Pulse Oximetry Randomized Trial 
 (SUPPORT),6 investigators reported that infants 
treated with the use of an oxygen-saturation tar-
get of 85 to 89%, as compared with a target of 
91 to 95%, had decreased rates of retinopathy 
of prematurity (8.6% vs. 17.9%, P<0.001) but in-
creased rates of death (19.9% vs. 16.2%, P = 0.045). 
At that time, patients were being recruited for 
the BOOST II trials, and after analyzing data 
from the original trials, the data and safety 
monitoring committees did not advise stopping 
recruitment.9
In December 2010, the data and safety moni-
toring committees in the United Kingdom, Aus-
tralian, and New Zealand undertook a pooled 
interim safety analysis,10 including data from 
the 2315 infants enrolled in the three BOOST II 
trials and the 1316 infants enrolled in SUPPORT.6 
The sole outcome that the committees analyzed 
was survival at 36 weeks’ gestation. Guidelines 
prespecified that the results would not be re-
leased to the investigators unless a difference in 
survival in all infants or in those recruited after 
the oximeter-calibration changes exceeded 3 SE 
(P<0.003). In the three trials reported here, mor-
tality at 36 weeks showed heterogeneity between 
the original oximeter-calibration algorithm and 
the revised algorithm (P = 0.006 for interaction). 
Among the 1260 infants for whom the original 
oximeter algorithm was used, there was no sig-
nificant between-group difference in mortality. 
However, in the 1055 infants for whom the revised 
algorithm was used, infants with an oxygen-
saturation target of 85 to 89%, as compared 
with those with a target of 91 to 95%, had an 
increased rate of death at 36 weeks (21.8% vs. 
13.3%, P<0.001). At that time, recruitment to the 
present trials in the United Kingdom and Aus-
tralia was closed.10 The present New Zealand 
trial had finished recruiting.
The primary outcome of the Neonatal Oxy-
genation Prospective Meta-analysis (NeOProM) 
Collaboration7 is death or severe neurosensory 
disability at 18 months to 2 years of age, cor-
rected for prematurity. SUPPORT recently report-
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ed no difference in this composite outcome but 
an increased rate of death at 18 to 22 months in 
infants in the group with a lower oxygen-satura-
tion target.11 Because a finding of increased 
mortality with a lower oxygen-saturation target 
could have an influence on clinical practice,10,11 
we now report a pooled analysis of individual 
patient data with respect to outcomes at hospital 
discharge in the United Kingdom, Australian, 
and New Zealand BOOST II trials.
Me thods
Patients
The planned study sample sizes were 1200 in-
fants each for the United Kingdom and Austra-
lian trials and 340 infants for the New Zealand 
trial. Infants were enrolled from March 1, 2006, 
until December 24, 2010. Randomization was 
performed centrally by computer and separately 
for each trial. In the United Kingdom, a minimi-
zation procedure was used to balance study-group 
assignment according to sex, gestational age, 
and center. In Australia and New Zealand, ran-
domization was stratified according to sex, gesta-
tional age, center, single birth or multiple births, 
and whether birth took place in the hospital 
where enrollment took place. Infants were eligible 
if they had been born within the past 24 hours and 
before 28 weeks’ gestation. Infants were exclud-
ed if they were considered to be unlikely to sur-
vive, had a major congenital abnormality, or would 
not be available for follow-up.
The ethics committee at each center approved 
the study before randomization. All parents pro-
vided written informed consent.
Enrollment and Treatment
Infants were randomly assigned to treatment with 
the use of an oxygen-saturation target of 85 to 
89% (lower-target group) or 91 to 95% (higher-
target group). To mask the intervention, the study 
oximeters were modified internally so that read-
ings of 85 to 95% showed an oxygen saturation 
that was either 3 percentage points higher or 3 per-
centage points lower than the actual value. Thus, 
a displayed reading of 90% corresponded to an 
actual oxygen saturation of 87% in one group 
and 93% in the other. To achieve the intended 
oxygen-saturation range in either group, clinical 
staff members targeted displayed readings in the 
range of 88 to 92%. Displayed oxygen-saturation 
values gradually reverted to actual values when 
the measured value was outside the range of 85 
to 95%.
Only study oximeters were used from the time 
of randomization until 36 weeks, unless infants 
died or were discharged home. If infants were in 
stable condition while breathing ambient air 
before 36 weeks, oximetry could be discontin-
ued, but if oximetry resumed before 36 weeks, 
study oximeters were used. Data regarding oxy-
gen saturation were downloaded and merged 
with chart data on which staff recorded the in-
spired oxygen concentration in blocks of either 
20 minutes (in the United Kingdom) or 60 min-
utes (in Australia and New Zealand) to enable 
assessment of compliance with target ranges.
Assessments
Data were recorded on case-report forms at each 
center and checked centrally. Retinopathy of pre-
maturity was classified according to the Interna-
tional Classification of Retinopathy of Prematu-
rity12 and is reported if infants were treated 
according to the Early Treatment for Retinopathy 
of Prematurity (ETROP) criteria.13 Necrotizing 
enterocolitis was listed if it required surgery or 
caused death. Oxygen treatment at 36 weeks was 
recorded in all three trials. In the United King-
dom, bronchopulmonary dysplasia was addition-
ally defined as requiring supplemental oxygen at 
36 weeks to maintain an actual oxygen satura-
tion of 90%.
When the oximeter-calibration algorithm was 
revised, infants continued to be treated with the 
use of the oximeter-calibration version to which 
they were originally assigned. Clinical staff mem-
bers were not informed about the nature of the 
software revision. No further training about 
oxygen-saturation targeting was provided.
Study Oversight
The BOOST II trials were funded and conducted 
independently, with similar protocols (available at 
NEJM.org). The Australian trial was funded by the 
National Health and Medical Research Council, 
the United Kingdom trial by the Medical Research 
Council, and the New Zealand trial by the New 
Zealand Health Research Council. Masimo sup-
plied the oximeters used in the study under lease, 
but company representatives were not involved in 
the design of the study, in the analysis of the 
data, or in the preparation of the manuscript.
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Statistical Analysis
A joint analysis plan prespecified that data from 
the three trials would be pooled and outcomes 
reported for all infants and for those who under-
went randomization before and after the revision 
of the oximeter-calibration algorithm.
All analyses were performed with the use of 
Stata SE 11.2 software (StatCorp). All analyses 
were performed separately by the trial statisti-
cians in the United Kingdom and Australia and 
were cross-checked. A two-sided P value of less 
than 0.05 was considered to indicate statistical 
significance without adjustment for multiple 
comparisons.
All analyses were performed on the intention-
to-treat principle at randomization, regardless of 
deviations from the protocol. Outcomes were 
summarized with the use of counts and percent-
ages for categorical variables and of means and 
standard deviations for normally distributed con-
tinuous variables. The magnitude and direction 
of treatment effects were expressed as relative 
risks, with 95% confidence intervals adjusted for 
country. Relative risks were calculated as the 
event rate in the lower-target group divided by 
the event rate in the higher-target group. Pre-
specified subgroup analyses according to the 
oximeter-calibration algorithm that was used were 
performed with a statistical test for interaction.
To compare the oxygen-saturation values, the 
percentage of time spent at each oxygen-satura-
tion value between 60% and 100% was calcu-
lated for each infant and pooled for all infants, 
for time treated with oxygen and for all time 
evaluated on the oximeter. Offset readings were 
adjusted back to the actual oxygen-saturation 
values. We used quadratic interpolation to esti-
mate the distribution of values affected by the 
transitioning back to actual values of offset 
readings in which the measured value was out-
side the range of 85 to 95%. A post hoc survival 
analysis was performed with the use of cumula-
tive-hazard plots to compare mortality before 
discharge in the two target groups.
R esult s
Patients
A total of 2448 infants were enrolled in the three 
trials (973 in the United Kingdom, 1135 in Aus-
tralia, and 340 in New Zealand). Of these in-
fants, 1261 (51.5%) were treated with the use of 
the original oximeter-calibration algorithm and 
1187 (48.5%) with the use of the revised algo-
rithm (Fig. 2). Baseline demographic and clinical 
characteristics were similar in the two target 
groups, among the three trials, and in the two 
algorithm groups (Table 1). Forest plots of pooled 
outcomes at hospital discharge are shown in Fig-
ure 3. Outcome data from the individual trials 
are provided in Tables S2.1 and S2.2 in the Sup-
plementary Appendix.
Rate of Death
Among the 1187 infants for whom the revised 
oximeter-calibration algorithm was used, those 
in the lower-target group had a higher rate of 
death than those in the higher-target group be-
fore hospital discharge (23.1% vs. 15.9%; relative 
risk in the lower-target group, 1.45; 95% confi-
dence interval [CI], 1.15 to 1.84; P = 0.002). These 
findings mean that 14 infants would need to be 
treated with a higher oxygen-saturation target in 
order to prevent 1 death. Among the 1261 infants 
for whom the original oximeter-calibration algo-
rithm was used, there were no significant be-
tween-group differences in outcomes at hospi-
tal discharge. There was heterogeneity between 
the rates of death among infants whose treat-
ment used the original oximeter-calibration al-
gorithm, as compared with the revised algorithm 
(P = 0.006 for interaction), but not for other out-
comes.
In all data combined, there was no significant 
difference in rate of death in the lower-target 
Figure 2 (facing page). Enrollment and Outcomes.
In the United Kingdom trial, screening of eligible infants 
was not recorded. Of the infants who underwent ran-
domization, all were included in the analysis except for 
the following 3: in the United Kingdom trial, 1 infant in 
the lower-target group for whom consent was not pro-
vided and 1 infant in the higher-target group who was 
found to be ineligible because of age; and in the Aus-
tralian trial, 1 infant in the lower-target group whose 
parents withdrew consent. A total of 23 infants (12 in 
the lower-target group and 11 in the higher-target group) 
did not receive the intended allocation at all times, 
mainly because of errors in oximeter allocation that 
were rectified later. The intervention was discontinued 
before it was completed in 35 infants, mainly because 
of parental or clinician wishes or because the infant 
was transferred to another center that was unable to 
continue the intervention. When the trials were stopped 
early after the interim safety analysis, the intervention 
was stopped in 43 infants in each of the two study groups.
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group, as compared with the higher-target group 
(19.2% vs. 16.6%; relative risk, 1.16, 95% CI, 
0.98 to 1.37; P = 0.09), but infants in the lower-
target group had a reduced rate of treatment for 
retinopathy of prematurity (10.6% vs. 13.5%; 
relative risk, 0.79; 95% CI, 0.63 to 1.00; P = 0.045) 
and an increased rate of necrotizing enterocoli-
tis requiring surgery or causing death (10.4% vs. 
8.0%; relative risk, 1.31; 95% CI, 1.02 to 1.68; 
P = 0.04). Although significantly fewer infants in 
the lower-target group were treated with oxygen 
at 36 weeks in the three trials, there was no 
2448 Underwent randomization
1135 Were in Australia
340 Were in New Zealand
973 Were in the United Kingdom
3041 Patients were assessed for eligibility
2454 Were in Australia
587 Were in New Zealand
1566 Were excluded
1319 Were in Australia
247 Were in New Zealand
275 Did not meet inclusion criteria
226 Were in Australia
49 Were in New Zealand
443 Declined to participate
384 Were in Australia
59 Were in New Zealand
848 Had other reasons
709 Were in Australia
139 Were in New Zealand
1224 Were assigned to lower-target oxygen 
 saturation (85–89%)
568 Were in Australia
170 Were in New Zealand
486 Were in the United Kingdom
1211 Received assigned intervention
560 Were in Australia
169 Were in New Zealand
482 Were in the United Kingdom
1 in the UK was randomized in error
12 Did not receive assigned inter-
vention
8 Were in Australia
1 Was in New Zealand
3 Were in the United Kingdom
1224 Were assigned to higher-target oxygen
saturation (91–95%)
567 Were in Australia
170 Were in New Zealand
487 Were in the United Kingdom
1212 Received assigned intervention
561 Were in Australia
169 Were in New Zealand
482 Were in the United Kingdom
1 in the UK was randomized in error
11 Did not receive assigned inter-
vention
6 Were in Australia
1 Was in New Zealand
4 Were in the United Kingdom
15 Discontinued intervention
1 Was in Australia
1 Was in New Zealand
13 Were in the United Kingdom
43 Discontinued intervention at
trial closure
16 Were in Australia
27 Were in the United Kingdom
1 in Australia was lost to
follow-up
20 Discontinued intervention
3 Were in Australia
17 Were in the United Kingdom
43 Discontinued intervention at
trial closure
14 Were in Australia
29 Were in the United Kingdom
1222 Were included in the intention-to-
treat analysis
567 Were in Australia
170 Were in New Zealand
485 Were in the United Kingdom
1223 Were included in the intention-to-
treat analysis
567 Were in Australia
170 Were in New Zealand
486 Were in the United Kingdom
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significant between-group difference in the rate 
of bronchopulmonary dysplasia, as defined phys-
iologically in the United Kingdom trial.
There were more deaths in the lower-target 
group, but no single cause dominated the differ-
ence (Table S3 in the Supplementary Appendix). 
Figure 4 shows cumulative hazard plots for mor-
tality before discharge, according to which ver-
sion of the oximeter-calibration algorithm was 
used. The difference in the proportions of in-
fants surviving in the two groups accumulated 
gradually after the first week after birth.
Effect of Oximeter Recalibration
Figure 1 summarizes pooled distributions of ox-
ygen saturation during the administration of 
supplemental oxygen (Fig. S1 and Tables S1.1 
through S1.4 in the Supplementary Appendix). 
With the original oximeter-calibration algorithm, 
there were fewer oxygen-saturation values be-
tween 87% and 90% in the two target groups and 
little separation between the peaks of the oxygen-
saturation distributions. With the revised algo-
rithm, the dip in oxygen-saturation values be-
tween 87% and 90% was eliminated, and there 
was clearer separation between the two target 
groups.
Per-Protocol Analysis and Adverse Events
The results of a per-protocol analysis that exclud-
ed 23 infants who did not receive the intended 
intervention were similar to the findings in the 
intention-to-treat analysis. The few adverse events 
that were reported are listed in full in Table S4 in 
the Supplementary Appendix.
Discussion
The present trials were closed early when a 
pooled interim safety analysis showed that in-
fants in the group treated with an oxygen-satura-
tion target of 85 to 89%, as compared with 91 to 
95%, had an increased rate of death at 36 weeks.10 
This report includes outcomes for all infants 
until hospital discharge. A substantial difference 
in mortality persisted, and other important out-
comes were influenced significantly by the tar-
geted oxygen-saturation range.
The between-group difference in the rate of 
death accrued over many weeks of the interven-
tion and was not attributable to any single cause 
of death. It is unclear why the rate of death was T
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higher in the lower-target group than in the 
higher-target group. Detailed post hoc analysis 
of the oxygen-saturation patterns of infants who 
survived and died will be required to further 
explore this issue. Interpretation of the results is 
complicated by the change in oximeter calibra-
tion approximately halfway through the trials. 
This modification rectified an artifact in the 
original oximeters that appeared to decrease the 
difference between groups in oxygen-saturation 
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Figure 3. Combined Discharge Outcomes from the Three Trials, According to Oxygen-Saturation Target and Status of the Oximeter- 
Calibration Algorithm.
Shown are discharge outcomes for all infants in the lower-target group for oxygen saturation (85 to 89%) and the higher-target group  
(91 to 95%) on the basis of whether their treatment involved the original algorithm for oximeter calibration or the revised algorithm.  
Also shown are P values for heterogeneity for such algorithm use, as calculated with the use of chi-square tests. Oxygen dependence  
at a gestational age of 36 weeks was measured in all three trials. In the United Kingdom trial, bronchopulmonary dysplasia was addition-
ally defined as requiring supplemental oxygen to maintain an actual oxygen saturation of 90% or more. Intraventricular hemorrhage was 
defined as only grade III or IV events, and patent ductus arteriosus was defined as a condition requiring medical or surgical treatment. 
The category of “other brain injury” included porencephaly, ventriculomegaly, posthemorrhagic hydrocephalus requiring a shunt or reser-
voir, periventricular leukomalacia, and cerebral atrophy. Relative risks and P values were adjusted for country.
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patterns. The revised Masimo oximeter-calibra-
tion algorithm may be more relevant to future 
clinical practice because it resembles the cali-
bration in other commonly used oximeters; the 
original calibration algorithm is no longer 
available.8
There was significant heterogeneity in treat-
ment effect between the original oximeter-cali-
bration algorithm and the revised algorithm 
with respect to mortality but not retinopathy of 
prematurity or necrotizing enterocolitis. This may 
be because each of these outcomes may be in-
fluenced at different oxygen saturations. The 
oxygen-saturation histograms in Figure 1 show 
that when the oximeter-calibration algorithm 
was revised, there was no increase in the propor-
tion of time spent with oxygen-saturation values 
below 85% in the lower-target group. This sug-
gests that the increase in mortality cannot be 
attributed to an increase in the time spent with 
very low oxygen-saturation values.
Infants in the lower-target group had a sig-
nificant decrease in the rate of treatment for 
retinopathy of prematurity, a finding that is 
consistent with the results of trials conducted in 
the 1950s1 and SUPPORT.6,11 Because treatment 
for this condition is usually effective, blindness 
was rare, with similar rates in the two target 
groups in SUPPORT.11 However, retinopathy of 
prematurity causes other structural and func-
tional eye abnormalities that can be visually dis-
abling,14 and these may become more common 
if the reported survival advantage with a higher 
oxygen saturation influences clinical practice. 
Treatment for retinopathy of prematurity was 
more frequent in the two target groups in the 
United Kingdom than in Australia and New 
Zealand, suggesting that treatment thresholds 
may have differed even though the same criteria 
were used.15
In the pooled data, the lower oxygen-satura-
tion target significantly increased the rate of 
necrotizing enterocolitis requiring surgery or 
causing death. This definition excludes milder 
cases of necrotizing enterocolitis with more sub-
jective features. It is plausible that a lower oxy-
gen saturation might influence bowel ischemia.
The increased proportion of infants receiving 
oxygen at 36 weeks in the higher-target group 
probably reflects, in part, the increased oxygen 
needed to achieve the target. As in SUPPORT,6 
when bronchopulmonary dysplasia was defined 
on the basis of a physiological test in the United 
Kingdom trial, there was no significant between-
group difference in this diagnosis.
With the original oximeters in the present 
trials, the peak median oxygen-saturation values 
while infants were receiving supplemental oxy-
gen were approximately 89% in the lower-target 
group and 92% in the higher-target group, as 
compared with 91% and 94%, respectively, in 
SUPPORT.6 Although the same intended targets 
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Figure 4. Cumulative Hazard Estimates for Death  before Hospital Discharge.
Data from the three BOOST II trials have been pooled and are plotted sep-
arately for infants who were treated with the use of the original oximeter-
calibration algorithm (Panel A) or the revised algorithm (Panel B). Cumulative 
hazard values were calculated with the use of the Nelson–Aalen estimator.
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were used, quite different oxygen-saturation pat-
terns were achieved in our studies, as compared 
with those in SUPPORT. When the oximeter-
calibration algorithm was revised, the lower-
target groups in the present trials spent more 
time in the intended range, and mortality in 
these groups increased. With greater or lesser 
adherence to the intended range, the effect of 
oxygen-saturation targets on mortality may vary, 
so the best estimate of the effect of oxygen satu-
ration on mortality is unknown. Other interven-
tions that influence oxygen targeting may influ-
ence mortality and should also be researched 
carefully.16
Monitoring of oxygen saturation has largely 
replaced the practice of monitoring the arterial 
partial pressure of oxygen (PaO2)17,18 and has 
effectively lowered the range of PaO2 for preterm 
infants, as compared with previously recom-
mended PaO2 targets.19,20 Infants in the lower-
target group may have had times when the PaO2 
was below 40 mm Hg.19 The optimal measure 
of oxygenation to guide clinical practice is not 
known.
Without the pooled interim safety analysis,10 
continued recruitment to the present trials might 
have resulted in potentially avoidable deaths in 
the lower-target group. Consensus is needed 
about the roles of data and safety monitoring 
committees of simultaneous, similar, indepen-
dent trials in respect to patient safety. The use of 
an interim analysis carries a statistical risk that, 
by chance, the observed effect might not repre-
sent the true effect that would have been shown 
if the trial had continued.21 Thus, the prespeci-
fied criteria for unmasking the results of the 
interim safety analysis11 required a difference in 
survival of 3 SE (99.73% confidence interval).
The clinically appropriate oxygen-saturation 
range for extremely preterm infants is unknown 
and may vary with advancing gestational and post-
natal age. The present trials and the SUPPORT 
trial suggest that targeting a range of 91 to 95% 
is safer than targeting a range of 85 to 89%, but 
other ranges have not been investigated. The 
follow-up results from SUPPORT show no sig-
nificant difference in rates of later disability.11 
The ongoing NeOProM Collaboration7 will even-
tually provide follow-up data on approximately 
5000 infants and may further inform clinical 
practice.
In conclusion, preterm infants born before 28 
weeks’ gestation with a target oxygen saturation 
of 85 to 89% had a significantly higher rate of 
death than did those with a target of 91 to 95% 
in a subgroup whose treatment involved an ox-
imeter-calibration algorithm similar to that in 
current use.8 Our findings strongly favor the 
avoidance of targeting an oxygen saturation of 
less than 90% among such infants, according to 
readings on current oximeters.6,10,11,22
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